- Home
- BBGI vs MYNZ Comparison
BBGI vs MYNZ Comparison
Compare BBGI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBGI | MYNZ |
|---|---|---|
| Founded | 1961 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.8M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBGI | MYNZ |
|---|---|---|
| Price | $5.03 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.5M | 195.9K |
| Earning Date | 11-10-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $220,174,714.00 | $659,935.00 |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.67 | $0.92 |
| 52 Week High | $26.37 | $8.20 |
Technical Indicators
Market Signals| Indicator | BBGI | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 53.19 |
| Support Level | $4.60 | $1.09 |
| Resistance Level | $5.60 | $1.29 |
| Average True Range (ATR) | 2.56 | 0.10 |
| MACD | -0.23 | 0.03 |
| Stochastic Oscillator | 4.23 | 60.56 |
Price Performance
Historical ComparisonAbout BBGI Beasley Broadcast Group Inc.
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.